Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
CONMED Community
NYSE:CNMD Community
3
Narratives
written by author
0
Comments
on narratives written by author
3
Fair Values set
on narratives written by author
Community Investing Ideas
CONMED
Popular
Undervalued
Overvalued
CONMED
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare
Key Takeaways Strong positioning in minimally invasive and robotic-assisted surgery, along with regulatory trends and innovation, drives recurring revenue growth and expands long-term market opportunities. Operational improvements and enhanced R&D investment are set to strengthen margins, earnings, and international sales while supporting sustained financial flexibility.
View narrative
US$61.00
FV
13.7% undervalued
intrinsic discount
5.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
1 day ago
author updated this narrative
CONMED
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Global Aging And Minimally Invasive Trends Will Empower Future Markets
Key Takeaways Focus on minimally invasive surgical solutions, operational efficiencies, and continuous innovation is expected to boost market share and drive sustained revenue and earnings growth. Expansion into emerging markets and improvement in global sales infrastructure are set to diversify revenue streams and support long-term international growth.
View narrative
US$80.00
FV
34.2% undervalued
intrinsic discount
6.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
23 days ago
author updated this narrative
CONMED
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Rising Costs And Supply Risks Will Impair Future Performance
Key Takeaways Rising cost controls, demographic stagnation, and industry consolidation are expected to constrain revenue growth and increase pricing pressure on CONMED's products. Underinvestment in R&D and geopolitical instability threaten long-term competitiveness by elevating supply costs and risking margin compression.
View narrative
US$55.00
FV
4.3% undervalued
intrinsic discount
4.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 months ago
author updated this narrative
Your Valuation for
CNMD
CNMD
CONMED
Your Fair Value
US$
Current Price
US$52.64
17.9% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-114m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.7b
Earnings US$144.4m
Advanced
Set Fair Value